4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-17-046332
Chief Executive Officer sold 5,500 shares at an average $16.49 ($90,704)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ciechanover Isaac E. Chief Executive Officer | 2017-07-24 | Sale | −2,500 | $16.89 | $42,225 | 453,578 | I: show line 1 in the form |
| Ciechanover Isaac E. Chief Executive Officer | 2017-07-24 | Sale | −300 | $17.32 | $5,196 | 453,278 | I: show line 2 in the form |
| Ciechanover Isaac E. Chief Executive Officer | 2017-07-25 | Sale | −2,500 | $15.97 | $39,925 | 450,778 | I: show line 3 in the form |
| Ciechanover Isaac E. Chief Executive Officer | 2017-07-25 | Sale | −200 | $16.79 | $3,358 | 450,578 | I: show line 4 in the form |
| Open-market sales · 5,500 sh · avg $16.49 · $90,704 | |||||||
Loading xslF345X03/doc4.xml…